Towards a Brucella vaccine for humans

FEMS Microbiology Reviews

Volumn 34, Issue 3, 2010, Pages 379-394

  Perkins, Stuart D ^a   Smither, Sophie J ^a   Atkins, Helen S ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Brucella; Brucellosis; Human; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BACTERIAL VACCINE; BRUCELLA VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CHLORAMPHENICOL; COTRIMOXAZOLE; DNA VACCINE; FREUND ADJUVANT; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 12; LIVE VACCINE; LUMAZINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ADOPTIVE TRANSFER; BACTERIAL TRANSMISSION; BIOLOGICAL WARFARE; BRUCELLA ABORTUS; BRUCELLA CANIS; BRUCELLA MELITENSIS; BRUCELLA SUIS; BRUCELLOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG RESEARCH; HUMAN; NONHUMAN; PATHOGENESIS; PRIMATE; REVIEW; RODENT; SEMLIKI FOREST ALPHAVIRUS; SPECIES DIFFERENCE; SQUIRREL; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BRUCELLA; BRUCELLA VACCINE; BRUCELLOSIS; DISEASE MODELS, ANIMAL; HUMANS;

ANIMALIA; BRUCELLA;

EID: 77950380555     PISSN: 01686445     EISSN: 15746976     Source Type: Journal    
DOI: 10.1111/j.1574-6976.2010.00211.x     Document Type: Review

References (130)

1. Allen CA, Adams LG Ficht TA (1998) Transposon-derived Brucella abortus rough mutants are attenuated and exhibit reduced intracellular survival. Infect Immun 66 : 1008 1016.
2. Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J, Walravens K Letesson JJ (2001) Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun 69 : 4816 4822.
3. Al-Mariri A, Tibor A, Lestrate P, Mertens P, De Bolle X Letesson JJ (2002) Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infect Immun 70 : 1915 1923.
4. Al-Tawfiq JA (2008) Therapeutic options for human brucellosis. Expert Rev Anti Infect Ther 6 : 109 120.
5. Andrews E, Salgado P, Folch H Onate A (2006) Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide-dismutase: II. Induction of specific CD8(+) cytotoxic lymphocytes and sensitized CD4(+) IFN-gamma-producing cell. Microbiol Immunol 50 : 389 393.
6. Araya LN, Elzer PH, Rowe GE, Enright FM Winter AJ (1989) Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus. J Immunol 143 : 3330 3337.
7. Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM Rice-Ficht AC (2008) Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge. Infect Immun 76 : 2448 2455.
8. Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Gomez G Rice-Ficht AC (2009) The Brucella abortus S19 ÄvjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect Immun 77 : 877 884.
9. Argiro L, Kohlstädt S, Henri S, Dessein H, Matabiau V, Paris P, Bourgois A Dessein AJ (2000) Identification of a candidate vaccine peptide on the 37 kDa Schistosoma mansoni GAPDH. Vaccine 18 : 2039 2048.
10. Ariza J, Gudiol F Pallares R (1992) Treatment of human brucellosis with doxycyclin plus rifampicin or doxycycline plus streptomycin. A randomized, double-blind study. Ann Intern Med 117 : 25 31.
11. Bae JE, Schurig GG Toth TE (2002) Mice immune responses to Brucella abortus heat shock proteins: use of baculovirus recombinant-expressing whole insect cells, purified Brucella abortus recombinant proteins, and a vaccinia virus recombinant as immunogens. Vet Microbiol 88 : 189 202.
12. Baek BK, Lee BO, Hur J, Rahman M, Lee SI Kakoma I (2005) Evaluation of the Sprague-Dawley rat as a model for vertical transmission of Brucella abortus. Can J Vet Res 69 : 305 308.
13. Baloglu S, Toth TE, Schurig GG, Sriranganathan N Boyle SM (2000) Humoral immune response of BALB/c mice to a vaccinia virus recombinant expressing Brucella abortus GroEL does not correlate with protection against a B. abortus challenge. Vet Microbiol 76 : 193 199.
14. Baloglu S, Boyle SM, Vemulapalli R, Sriranganathan N, Schurig GG Toth TE (2005) Immune responses of mice to vaccinia virus recombinants expressing either Listeria monocytogenes partial listeriolysin or Brucella abortus ribosomal L7/L12 protein. Vet Microbiol 109 : 11 17.
15. Bang B (1897) Die Aetiologie des seuchenhaften ('infectiosen') verwerfens. Z Thiermed (Jena) 1 : 241 278 [Cited in: Evans AC (1950) Comments on the early history of human brucellosis. Brucellosis (Larson CH & Soule MH, eds), pp. 1-8. Waverley Press, Baltimore, MD].
16. Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F et al 2005) A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 175 : 7297 7302.
17. Bertotto A, Gerli R, Spinozzi F, Muscat C, Scalise F, Castellucci G, Sposito M, Candio F Vaccaro R (1993) Lymphocytes bearing the gamma delta T cell receptor in acute Brucella melitensis infection. Eur J Immunol 23 : 1177 1180.
18. Brandsma JL, Shlyankevich M, Zelterman D Su Y (2007) Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine. Vaccine 25 : 6158 6163.
19. Braude AI (1951) Studies in the pathology and pathogenesis of experimental brucellosis. I. A comparison of the pathogenicity of Brucella abortus, Brucella melitensis, and Brucella suis for guinea pigs. J Infect Dis 89 : 76 86.
20. Bruce D (1887) Note on the discovery of a microorganism in Malta fever. Practitioner 39 : 161 170.
21. Capasso L (2002) Bacteria in two-millennia-old cheese, and related epizoonoses in roman populations. J Infection 45 : 122 127.
22. Cassataro J, Estein SM, Pasquevich KA, Velikovsky CA, de la Barrera S, Bowden R, Fossati CA Giambartolomei GH (2005a) Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4(+) T helper 1 response that protects against Brucella melitensis infection. Infect Immun 73 : 8079 8088.
23. Cassataro J, Velikovsky CA, de la Barrera S, Estein SM, Bruno L, Bowden R, Pasquevich KA, Fossati CA Giambartolomei GH (2005b) A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect Immun 73 : 6537 6546.
24. Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Velikovsky CA, de la BS, Bowden R, Fossati CA, Giambartolomei GH Goldbaum FA (2007a) A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine 25 : 4437 4446.
25. Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Zwerdling A, de la BS, Bowden R, Fossati CA, Giambartolomei GH Goldbaum FA (2007b) A DNA vaccine coding for the quimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine 25 : 5958 5967.
26. Cassataro J, Velikovsky CA, Bruno L, Estein SM, de la BS, Bowden R, Fossati CA Giambartolomei GH (2007c) Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting. Clin Vaccine Immunol 14 : 869 874.
27. Cespedes S, Andrews E, Folch H Onate A (2000) Identification and partial characterisation of a new protective antigen of Brucella abortus. J Med Microbiol 49 : 165 170.
28. Colmenero Castillo JD, Hernandez Marquez S, Reguera Iglesias JM, Cabrera Franquelo F, Rius Diaz F Alonso A (1989) Comparative trial of doxycycline plus streptomycin versus doxycycline plus rifampin for the therapy of human brucellosis. Chemotherapy 35 : 146 152.
29. Commander NJ, Spencer SA, Wren BW MacMillan AP (2007) The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Vaccine 25 : 43 54.
30. Corbel MJ (1989) Microbiology of the genus Brucella. Brucellosis: Clinical and Laboratory Aspects (Young EJ Corbel MJ, eds), pp. 53 72. CRC Press Inc.
31. Crawford RP, Huber JD Adams BS (1990) Epidemiology and surveliance. Animal Brucellosis (Nielsen K Duncan JR, eds), pp. 131 151. CRC Press Inc.
32. Delpino AV, Cassataro J, Fossati CA, Goldbaum FA Baldi PC (2006) Brucella outer membrane protein Omp31 is a haemin-binding protein. Microbes Infect 8 : 1203 1208.
33. Delpino MV, Estein SM, Fossati CA, Baldi PC Cassataro J (2007) Vaccination with Brucella recombinant DnaK and SurK proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine 25 : 6721 6729.
34. Dobano C, Rogers WO, Gowda K Doolan DL (2007) Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines. Immunol Lett 111 : 92 102.
35. Dornand J, Gross A, Lafont V, Liautard J, Oliaro J Liautard JP (2002) The innate immune response against Brucella in humans. Vet Microbiol 90 : 383 394.
36. Dranovskaya EA (1991) New approaches to brucellosis vaccination of people with high risk of infection. Brucella and Brucellosis in Man and Animals (Tumbay E, Hilmi S Ang O, eds), pp. 87 100. Ege University Press, Imzir, Turkish Microbiology Society.
37. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR Dean HJ (2006) Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24 : 4475 4481.
38. Elberg SS Henderson DW (1948) Respiratory pathogenicity of Brucella. J Infect Dis 82 : 302 306.
39. Elzer PH, Hagius SD, Davis DS, DelVecchio VG Enright FM (2002) Characterization of the caprine model for ruminant brucellosis. Vet Microbiol 90 : 425 431.
40. Elzner PH, Jacobson RH, Nielsen KH, Douglas JT Winter AJ (1994) BALB/c mice infected with Brucella abortus express protracted polyclonal responses of both IgG2a and IgG3 isotypes. Immunol Lett 42 : 145 150.
41. Enright FM (1990) The pathogenesis and pathobiology of Brucella infection in domestic animals. Animal Brucellosis (Mielsen K Duncan JR, eds), pp. 301 320. CRC Press Inc.
42. Ewalt DR, Payeur JB, Martin BM, Cummins DR Miller WG (1994) Characteristics of a Brucella species from a bottle-nosed dolphin (Tursiops truncatus). J Vet Diagn Invest 6 : 448 452.
43. Fernandes DM Baldwin CL (1995) Interleukin-10 down-regulates protective immunity to Brucella abortus. Infect Immun 63 : 1130 1133.
44. Ficht TA (2002) Discovery of Brucella virulence mechanisms using mutational analysis. Vet Microbiol 90 : 311 315.
45. Fugier E, Pappas G Gorvel JP (2007) Virulence factors in brucellosis: implications for aetiopathogenesis and treatment. Expert Rev Mol Med 9 : 1 10.
46. Fuller DH, Rajakumar PA, Wilson LA et al 2002) Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol 76 : 3309 3317.
47. Gonzalez-Smith A, Vemulapalli R, Andrews E Onate A (2006) Evaluation of Brucella abortus DNA vaccine by expression of Cu-Zn superoxide dismutase antigen fused to IL-2. Immunobiology 211 : 65 74.
48. Greenfield RA, Drevets DA, Machado LJ, Voskuhl GW, Cornea P Bronze MS (2002) Bacterial pathogens as biological weapons and agents of bioterrorism. Am J Med Sci 323 : 299 315.
49. Grillü MJ, Bosseray N Blasco JM (2000) In vitro markers and biological activity in mice of seed lot strains and commercial Brucella melitensis Rev 1 and Brucella abortus B19 vaccines. Biologicals 28 : 119 127.
50. Hadjichristodoulou C, Voulgaris P, Toulieres L, Babalis T, Manetas G, Goutziana G, Kastritis I Tselentis I (1994) Tolerance of the human brucellosis vaccine and the intradermal reaction test for brucellosis. Eur J Clin Microbiol 13 : 129 134.
51. Haynes JR, Fuller DH, McCabe D, Swain WF Widera G (1996) Induction and characterization of humoral and cellular immune responses elicited via gene gun-mediated nucleic acid immunization. Adv Drug Deliver Rev 21 : 3 18.
52. Herzberg M, Elberg SS Meyer KF (1953) Immunization against Brucella infection. II. Effectiveness of a streptomycin-dependent strain of Brucella melitensis. J Bacteriol 66 : 600 605.
53. Hoffmann EM Houle JJ (1995) Contradictory roles for antibody and complement in the interaction of Brucella abortus with its host. Crit Rev Microbiol 21 : 153 163.
54. Hong PC, Tsolis RM Ficht TA (2000) Identification of genes required for chronic persistence of Brucella abortus in mice. Infect Immun 62 : 4102 4107.
55. Huddleston IF Hallman ET (1929) The pathogenicity of the species of the genus Brucella for monkeys. J Infect Dis 45 : 293 303.
56. Ilyinskii PO, Meriin AB, Gabai VL, Zhirnov OP, Thoidis G Shneider AM (2008) Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response. Vaccine 26 : 2177 2185.
57. Izadjoo MJ, Polotsky Y, Mense MG, Bhattacharjee AK, Paranavitana CM, Hadfield TL Hoover DL (2000) Impaired control of Brucella melitensis infection in Rag1-deficient mice. Infect Immun 68 : 5314 5320.
58. Jerusalmi A, Morris-Downes MM, Sheahan BJ Atkins GJ (2003) Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis. Mol Ther 8 : 886 894.
59. Jiménez de Bagüés MP, Marin CM, Barberan M Blasco JM (1993) Evaluation of vaccines and of antigen therapy in a mouse model for Brucella ovis. Vaccine 11 : 61 66.
60. Kahl-McDonagh MM, Elzer PH, Hagius SD et al 2006) Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis. Vaccine 24 : 5169 5177.
61. Kahl-McDonagh MM, Arenas-Gamboa AM Ficht TA (2007) Aerosol infection of BALB/c Mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge. Infect Immun 75 : 4923 4932.
62. Kaufmann AF, Fox MD, Boyce JM, Anderson DC, Potter ME, Martone WJ Patton CM (1980) Airborne spread of brucellosis. Ann NY Acad Sci 353 : 105 114.
63. Ko J, Gendron-Fitzpatrick A, Ficht TA Splitter GA (2002) Virulence criteria for Brucella abortus strains as determined by interferon regulatory factor 1-deficient mice. Infect Immun 70 : 7004 7012.
64. Kurar E Splitter GA (1997) Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response. Vaccine 15 : 1851 1857.
65. Leclerq S, Harms JS, Rosinha GMS, Azevedo V Oliveira SC (2002) Induction of a Th1-type of immune response but not protective immunity by intramuscular DNA immunisation with Brucella abortus GroEL heat-shock gene. J Med Microbiol 51 : 20 26.
66. Leung L, Srivastava IK, Kan E, Legg H, Sun Y, Greer C, Montefiori DC, zur Megede J Barnett SW (2004) Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. Aids 18 : 991 1001.
67. Lopez-Merino A, Asselineau J, Serre A, Roux J, Bascoul S Lacave C (1976) Immunization by an insoluble fraction extracted from Brucella melitensis: immunological and chemical characterization of the active substances. Infect Immun 13 : 311 321.
68. Luo D, Bing N, Li P, Shi W, Zhang SL, Han Y, Mao LW, He YD, Wu YZ Wang XL (2006a) Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice. Infect Immun 74 : 2734 2741.
69. Luo DY, Li P, Xing L, Zhao GY, Shi W, Zhang SL Wang XL (2006b) DNA vaccine encoding L7/L12-P39 of Brucella abortus induces protective immunity in BALB/c mice. Chinese Med J-Peking 119 : 331 334.
70. Mallick AI, Singha H, Khan S, Anwar T, Ansari MA, Khalid R, Chaudhuri P Owais M (2007) Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis. Vaccine 25 : 7873 7884.
71. Marano N, Plikaytis BD Anthrax Vaccine Research Program Working Group et al 2008) Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. J Am Med Assoc 300 : 1532 1543.
72. McConnell MJ, Hanna PC Imperiale MJ (2007) Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. Mol Ther 15 : 203 210.
73. Meador VP Deyoe BL (1986) Experimentally induced Brucella abortus infection in pregnant goats. Am J Vet Res 47 : 2337 2342.
74. Mense MG, Van De Verg LL, Bhattacharjee AK, Garrett JL, Hart JA, Lindler LE, Hadfield TL Hoover DL (2001) Bacteriologic and histologic features in mice after intranasal inoculation of Brucella melitensis. Am J Vet Res 62 : 398 405.
75. Mense MG, Borschel RH, Wilhelmsen CL, Pitt ML Hoover DL (2004) Pathologic changes associated with brucellosis experimentally induced by aerosol exposure in rhesus macaques (Macaca mulatta). Am J Vet Res 65 : 644 652.
76. Miyoshi A, Bermudez-Humaran LG, Ribeiro LA, Le Loir Y, Oliveira SC, Langella P Azevedo V (2006) Heterologous expression of Brucella abortus GroEL heat-shock protein in Lactococcus lactis 8. Microb Cell Fact 5 : 14.
77. Montaraz JA, Winter AJ, Hunter DM, Sowa BA, Wu AM Adams LG (1986) Protection against Brucella abortus in mice with O-polysaccharide-specific monoclonal antibodies. Infect Immun 51 : 961 963.
78. Montejo JM, Alberola I, Glez-Zarate P, Alvarez A, Alonso J, Canovas A Aguirre C (1993) Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis. Clin Infect Dis 16 : 671 676.
79. Munoz-Montesino C, Andrews E, Rivers R, Gonzalez-Smith A, Moraga-Cid G, Folch H, Cespedes S Onate AA (2004) Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4(+) and CD8(+) T cells. Infect Immun 72 : 2081 2087.
80. Murphy EA, Sathiyaseelan J, Parent MA, Zou BX Baldwin CL (2001) Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology 103 : 511 518.
81. Nakano I, Maertens G, Major ME, Vitvitski L, Dubuisson J, Fournillier A, De Martynoff G, Trepo C Inchauspe G (1997) Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol 71 : 7101 7109.
82. Noviello S, Gello R, Kelly M, Limberger RJ, DeAngelis K, Cain L, Wallace B Dumas N (2004) Laboratory-acquired brucellosis. Emerg Infect Dis 10 : 1848 1850.
83. Oliaro J, Dudal S, Liautard J, Andrault JB, Liautard JP Lafont V (2005) V9V2 T cells use a combination of mechanisms to limit the spread of the pathogenic bacteria Brucella. J Leukocyte Biol 77 : 652 660.
84. Oliveira SC Splitter GA (1995) CD8+ type 1 CD44hi CD45 RBlo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I- and class II-deficient mice. Eur J Immunol 25 : 2551 2557.
85. Oliveira SC Splitter GA (1996a) Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine 14 : 959 962.
86. Oliveira SC Splitter GA (1996b) Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine 14 : 959 962.
87. Oliveira SC, Harms JS, Banai M Splitter G (1996) Recombinant Brucella abortus proteins that induce proliferation and IFN-gamma secretion by CD4+ T cells from Brucella-vaccinated mice and delay-type hypersensitivity in sensitized guinea pigs. Cell Immunol 172 : 262 268.
88. Olsen SC, Waters WR Stoffregen WS (2007) An aerosolized Brucella spp. challenge model for laboratory animals. Zoonoses Public Health 54 : 281 285.
89. Onate AA, Vemulapalli R, Andrews E, Schurig GG, Boyle S Folch H (1999) Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide dismutase protects mice against virulent B. abortus. Infect Immun 67 : 986 988.
90. Onate AA, Cespedes S, Cabrera A, Rivers R, Gonzalez A, Munoz C, Folch H Andrews E (2003) A DNA vaccine encoding Cu, Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 71 : 4857 4861.
91. Onate AA, Donoso G, Moraga-Cid G, Folch H, Cespedes S Andrews E (2005) An RNA vaccine based on recombinant semliki forest virus particles expressing the Cu, Zn superoxide dismutase protein of Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 73 : 3294 3300.
92. Palmer MV Cheville NF (1997) Effects of oral or intravenous inoculation with Brucella abortus strain RB51 vaccine in beagles. Am J Vet Res 58 : 851 856.
93. Pappas G, Akritidis N, Bosilkovski M Tsianos E (2005) Brucellosis. New Engl J Med 352 : 2325 2336.
94. Pasquevich KA, Estein SM, Garcia Samartino C, Zwerdling A, Coria LM, Barrionuevo P, Fossati CA, Giambartolomei GH Cassataro J (2008) Immunization with recombinant Brucella spp. outer membrane proteins Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infect Immun 77 : 436 445.
95. Pavolv H, Hogarth M, McKenzie IF Cheers C (1982) In vivo and in vitro effects of monoclonal antibody to Ly antigens on immunity to infection. Cell Immunol 71 : 127 138.
96. Payne LG, Fuller DH Haynes JR (2002) Particle-mediated DNA vaccination of mice, monkeys and men: looking beyond the dogma. Curr Opin Mol Ther 4 : 459 466.
97. Percy DH, Egwu IN Jonas AM (1972) Experimental Brucella canis infection in the monkey (Macaca arctoides). Can J Comp Med 36 : 221 225.
98. Perkins SD, O'Brien LM Phillpotts RJ (2006) Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination. Vaccine 24 : 3440 3445.
99. Phillips M, Deyoe BL Canning PC (1989) Protection of mice against Brucella abortus infection by inoculation with monoclonal antibodies recognizing Brucella O-antigen. Am J Vet Res 50 : 2158 2161.
100. Plotkin SL Plotkin SA (2004) A short history of vaccination. Vaccines (Plotkin SA Orenstein WA, eds), pp. 1 15. Elsevier
101. Purcell BK, Hoover DL Friedlander AM (2007) Brucellosis. Medical Aspects of Biological Warfare (Dembek ZF, ed), pp. 185 198. The Office of the Surgeon General at TMM Publications
102. Rajashekara G, Krepps M, Eskra L, Mathison A, Montgomery A, Ishii Y Splitter G (2005) Unraveling Brucella genomics and pathogenesis in immunocompromised IRF-1(-/-) mice. Am J Reprod Immunol 54 : 358 368.
103. Rasooly G, Boros DL Gerichter C (1968) Immunization against Brucella with killed vaccines. Israel J Med Sci 4 : 246 251.
104. Renoux G, Renoux M Tinelli R (1973) Phenol water fractions from smooth Brucella abortus and Brucella melitensis: immunochemical analysis and biological behaviour. J Infect Dis 127 : 139 148.
105. Rosinha GMS, Myioshi A, Azevedo V, Splitter GA Oliveira SC (2002) Molecular and immunological characterisation of recombinant Brucella abortus glyceraldehyde-3-phosphate-dehydrogenase, a T- and B-cell reactive protein that induces partial protection when co-administered with an interleukin-12- expressing plasmid in a DNA vaccine formulation. J Med Microbiol 51 : 661 671.
106. Ross HM, Jahans KL, MacMillan AP, Reid RJ, Thompson PM Foster G (1996) Brucella species infection in North Sea seal and cetacean populations. Vet Rec 138 : 647 648.
107. Saez D, Guzman I, Andrews E, Cabrera A Onate AAC (2008) Evaluation of Brucella abortus DNA and RNA vaccines expressing Cu-Zn superoxide dismutase (SOD) gene in cattle. Vet Microbiol 129 : 396 403.
108. Sarinas PSA Chitkara K (2003) Brucellosis. Semin Respir Infect 18 : 168 182.
109. Schlabritz-Loutsevitch NE, Whatmore AM, Quance CR et al 2009) A novel Brucella isolate in association with two cases of stillbirth in non-human primates - first report. J Med Primatol 38 : 70 73.
110. Scholz HC, Hubalek Z, Sedlacek I et al 2008) Brucella microti sp. nov., isolated from the common vole Microtus arvalis. Int J Syst Evol Micr 58 : 375 382.
111. Scholz HC, Nockler K, Gollner C et al 2009) Brucella inopinata sp. nov., isolated from a breast implant infection. Int J Syst Evol Micr DOI :.
112. Shakir RA (1986) Neurobrucellosis. Postgrad Med J 62 : 177 179.
113. Shi D, Song Y Li Y-J (2006) Progress on Lactococcus lactis expressing heterologous antigens as live mucosal vaccines. Weishengwu Xuebao 46 : 680 683.
114. Singha H, Mallick AI, Jana C, Isore DP, Goswami TK, Srivastava SK, Azevedo VA, Chaudhuri P Owais M (2008) Escheriosomes entrapped DNA vaccine co-expressing Cu-Zn superoxide dismutase and IL-18 confers protection against Brucella abortus. Microbes Infect 10 : 1089 1096.
115. Smither SJ, Perkins SD, Davies C, Stagg AJ, Nelson M Atkins HS (2009) Development and characterization of mouse models of infection with aerosolized Brucella melitensis and Brucella suis. Clin Vaccine Immunol 16 : 779 783.
116. Solera J, Martinez-Alfaro E, Espinosa A, Castillejos ML, Geijo P Rodriguez-Zapata M (1998) Multivariate model for predicting relapse in human brucellosis. J Infection 36 : 85 92.
117. Spink WW, Hall JW, Finstad J Mallet E (1962) Immunization with viable Brucella organisms. Results of a safety test in humans. B World Health Organ 26 : 409 419.
118. Thorpe BD, Sidwell RW Lundgren DL (1967) Experimental studies with four species of Brucella in selected wildlife, laboratory, and domestic animals. Am J Trop Med Hyg 16 : 665 674.
119. Velikovsky CA, Cassataro J, Giambartolomei GH, Goldbaum FA, Estein S, Bowden RA, Bruno L, Fossati CA Spitz M (2002) A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 70 : 2507 2511.
120. Velikovsky CA, Goldbaum FA, Cassataro J, Estein S, Bowden RA, Bruno L, Fossati CA Giambartolomei GH (2003) Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation. Infect Immun 71 : 5750 5755.
121. Vemulapalli R, Duncan AJ, Boyle SM, Sriranganathan N, Toth TE Schurig GG (1998) Cloning and sequencing of yajC and secD homologs of Brucella abortus and demonstration of immune responses to YajC in mice vaccinated with B.abortus RB51. Infect Immun 66 : 5684 5691.
122. Vershilova PA (1961) The use of live vaccine for vaccination of human beings against brucellosis in the USSR. B World Health Organ 24 : 85 89.
123. Williamson ED, Flick-Smith HC, LeButt C, Rowland CA, Jones SM, Waters EL, Miller J, Packer PJ Irving M (2005) Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 73 : 3598 3608.
124. Winter AJ, Duncan JR, Santisteban CG, Douglas JT Adams LG (1989) Capacity of passively administered antibody to prevent establishment of Brucella abortus infection in mice. Infect Immun 57 : 3438 3444.
125. Xin KQ, Hoshino Y, Toda Y et al 2003) Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood 102 : 223 228.
126. Yang XH, Hudson M, Walters N, Bargatze RF Pascual DW (2005) Selection of protective epitopes for Brucella melitensis by DNA vaccination. Infect Immun 73 : 7297 7303.
127. Yang XH, Walters N, Robison A, Trunkle T Pascual DW (2007) Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. Vaccine 25 : 2261 2268.
128. Yu DH, Hu XD Cai H (2007) A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. Dna Cell Biol 26 : 435 443.
129. Zhan YF Cheers C (1998) Control of IL-12 and IFN-gamma production in response to live or dead bacteria by TNF and other factors. J Immunol 161 : 1447 1453.
130. Zhan YF, Liu ZQ Cheers C (1996) Tumor necrosis factor alpha and interleukin-12 contribute to resistance to the intracellular bacterium Brucella abortus by different mechanisms. Infect Immun 64 : 2782 2786.